Roxadustat Market Report 2026

The roxadustat market size has grown strongly in recent years. It will grow from $6.86 billion in 2025 to $7.33 billion in 2026 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to high prevalence of chronic kidney disease, dependence on erythropoiesis-stimulating agents, hospital-based anemia management, limited oral anemia therapies, growth in dialysis centers.

The roxadustat market size is expected to see strong growth in the next few years. It will grow to $9.56 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to rising global anemia burden, increasing preference for oral therapies, expansion of ckd patient population, growing outpatient anemia management, improved access to innovative anemia drugs. Major trends in the forecast period include rising adoption of oral anemia therapies, growing use of hif-phi drugs, increased focus on ckd-associated anemia, shift away from injectable esas, expansion of anemia treatment accessibility.

The increasing prevalence of chronic kidney disease (CKD) is anticipated to drive expansion in the Roxadustat market. Chronic kidney disease (CKD) is a prolonged condition in which the kidneys progressively lose their ability to function effectively, potentially resulting in kidney failure without treatment. Globally, the number of people impacted by CKD is growing due to factors like aging populations, rising diabetes and hypertension rates, and poor lifestyle choices. Roxadustat aids in managing CKD by promoting erythropoietin production, which boosts red blood cell formation and combats the anemia often linked to the disease, ultimately enhancing kidney performance and patients' quality of life. For instance, in June 2023, Kidney Research UK, a UK-based charity, reported that by 2033, the number of people with CKD stages 3-5 is projected to reach 3.9 million. Therefore, the growing prevalence of chronic kidney disease (CKD) is fueling the Roxadustat market's growth.

Major companies in the roxadustat market prioritize creating real-world evidence through observational registry studies to bolster the long-term value, safety, and usage patterns of their HIF PH inhibitor therapies; this evidence draws from clinical data in routine settings outside controlled trials, capturing true patient experiences, with the market funding large-scale studies that payers and regulators increasingly use for evaluations - for instance, in May 2024, UK-based Astellas Pharma launched the WINE study via Germany's WiNe Registry, a non-interventional cohort tracking outcomes, dosing, and hemoglobin responses in EVRENZO (roxadustat) patients, thereby demonstrating efficacy in real-world CKD groups and aiding reimbursement choices - ultimately driving roxadustat market growth.

In February 2024, FibroGen Inc., a US-based biopharmaceutical firm, revealed a collaboration with Astellas Pharma Inc. and AstraZeneca PLC. Through this partnership, FibroGen seeks to advance and market Roxadustat for treating anemia in conditions such as chronic kidney disease (CKD) and myelodysplastic syndromes (MDS). Astellas Pharma Inc. is a Japan-based pharmaceutical company, while AstraZeneca PLC is a UK-based pharmaceutical company engaged in the development and commercialization of Roxadustat.

Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy's Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.

North America was the largest region in the Roxadustat market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the roxadustat market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased the cost of imported pharmaceutical intermediates used in roxadustat production and formulation activities. These impacts are most evident in hospital and specialty pharmacy supply channels, where treatment availability and pricing are closely monitored. Asia Pacific regions have been particularly affected due to reliance on cross border sourcing for key intermediates. Rising tariff related expenses have influenced procurement planning, pricing strategies, and inventory management. Positively, tariffs are accelerating localized manufacturing investments, expanding domestic production capacity, and improving long term supply stability.

The roxadustat market research report is one of a series of new reports that provides roxadustat market statistics, including roxadustat industry global market size, regional shares, competitors with a roxadustat market share, detailed roxadustat market segments, market trends and opportunities, and any further data you may need to thrive in the roxadustat industry. This roxadustat market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) that stabilizes hypoxia-inducible factors, resulting in boosted erythropoietin production, better iron absorption, and enhanced hemoglobin synthesis without requiring external erythropoiesis-stimulating agents. It treats anemia by targeting low hemoglobin levels in individuals with chronic kidney disease and possibly other disorders that hinder red blood cell production.

Roxadustat primarily comes in 20 mg and 50 mg strengths. Roxadustat 20 mg acts as an oral hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor for treating anemia linked to chronic kidney disease, by boosting the body's own erythropoietin production. It comes in oral tablet form and reaches patients through channels like hospitals, specialty pharmacies, and dialysis centers. Roxadustat treats anemia related to chronic kidney disease and other conditions.

The Roxadustat market consists of sales of products such as 70 mg, 100 mg, and 150 mg film-coated tablets. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.